- Home
- VRCA vs IMRX Comparison
VRCA vs IMRX Comparison
Compare VRCA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- IMRX
- Stock Information
- Founded
- VRCA 2013
- IMRX 2008
- Country
- VRCA United States
- IMRX United States
- Employees
- VRCA N/A
- IMRX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- IMRX Health Care
- Exchange
- VRCA Nasdaq
- IMRX Nasdaq
- Market Cap
- VRCA 43.0M
- IMRX 62.7M
- IPO Year
- VRCA 2018
- IMRX 2021
- Fundamental
- Price
- VRCA $0.46
- IMRX $1.41
- Analyst Decision
- VRCA Hold
- IMRX Strong Buy
- Analyst Count
- VRCA 5
- IMRX 2
- Target Price
- VRCA $6.00
- IMRX $12.50
- AVG Volume (30 Days)
- VRCA 400.9K
- IMRX 125.1K
- Earning Date
- VRCA 05-12-2025
- IMRX 05-13-2025
- Dividend Yield
- VRCA N/A
- IMRX N/A
- EPS Growth
- VRCA N/A
- IMRX N/A
- EPS
- VRCA N/A
- IMRX N/A
- Revenue
- VRCA $7,566,000.00
- IMRX N/A
- Revenue This Year
- VRCA $127.58
- IMRX N/A
- Revenue Next Year
- VRCA $88.06
- IMRX N/A
- P/E Ratio
- VRCA N/A
- IMRX N/A
- Revenue Growth
- VRCA 47.66
- IMRX N/A
- 52 Week Low
- VRCA $0.38
- IMRX $1.00
- 52 Week High
- VRCA $11.41
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- VRCA 46.88
- IMRX 46.91
- Support Level
- VRCA $0.45
- IMRX $1.41
- Resistance Level
- VRCA $0.50
- IMRX $1.51
- Average True Range (ATR)
- VRCA 0.06
- IMRX 0.09
- MACD
- VRCA 0.00
- IMRX 0.03
- Stochastic Oscillator
- VRCA 29.44
- IMRX 66.93
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.